Moderna大涨超11%，公司成本控制见效，新药重振市场信心
周二，Moderna盘中大涨超11%。虽然Moderna近期业绩不佳,2024年亏损高达36亿美元,营收从疫情高峰期的68亿美元骤降至仅32亿美元。但公司的成本控制措施初见成效,开支较2023年下降了27%。展望2025年,Moderna计划与2024年相比再削减10亿美元开支。
更为重要的是,市场对Moderna多达10款新药管线重燃了信心。其中,Moderna预计到2027年实现10款以上新产品获批,包括流感疫苗、巨细胞病毒疫苗等。而公司的旗舰新药RSV疫苗mRESVIA、下一代新冠疫苗等也已进入监管审批关键期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10